Co-Diagnostics, Inc.
For the period ended Sep 30, 2025. Filed Nov 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 13, 2025
CODX$0.29-9.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 1. Condensed Consolidated Balance Sheets
CONDENSED CONSOLIDATED BALANCE SHEETS
| September 30, 2025 | December 31, 2024 | |
|---|---|---|
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $11,443,943 | $2,936,544 |
| Marketable investment securities | - | 26,811,098 |
| Accounts receivable, net | 55,905 | 132,570 |
| Inventory, net | 1,089,956 | 1,072,724 |
| Income taxes receivable | 923,217 | - |
| Prepaid expenses and other current assets | 541,946 | 1,338,762 |
| Total current assets | 14,054,967 | 32,291,698 |
| Property and equipment, net | 2,485,112 | 2,761,280 |
| Operating lease right-of-use asset | 1,439,779 | 2,114,876 |
| Intangible assets, net | 26,101,000 | 26,101,000 |
| Investment in joint venture | 659,903 | 731,065 |
| Total assets | $44,740,761 | $63,999,919 |
| Liabilities and stockholders’ equity | ||
| Current liabilities | ||
| Accounts payable | $1,458,397 | $3,294,254 |
| Accrued expenses | 1,204,660 | 2,562,169 |
| Operating lease liability, current | 744,156 | 915,619 |
| Contingent consideration liabilities, current | 239,955 | 502,819 |
| Deferred revenue | 45,557 | 40,857 |
| Total current liabilities | 3,692,725 | 7,315,718 |
| Long-term liabilities | ||
| Income taxes payable | 491,848 | 713,643 |
| Operating lease liability | 727,943 | 1,236,560 |
| Contingent consideration liabilities | - | 422,080 |
| Total long-term liabilities | 1,219,791 | 2,372,283 |
| Total liabilities | 4,912,516 | 9,688,001 |
| Commitments and contingencies (Note 10) | - | |
| Stockholders’ equity | ||
| Convertible preferred stock, $0.001 par value; 5,000,000 shares authorized; 0 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively | - | - |
| Common stock, $0.001 par value; 100,000,000 shares authorized; 52,991,260 shares issued and 48,142,582 shares outstanding as of September 30, 2025 and 37,902,222 shares issued and 33,053,544 shares outstanding as of December 31, 2024 | 52,991 | 37,902 |
| Treasury stock, at cost; 4,848,678 shares held as of September 30, 2025 and December 31, 2024, respectively | (15,575,795) | (15,575,795) |
| Additional paid-in capital | 109,447,214 | 102,472,210 |
| Accumulated other comprehensive income | 94,888 | 418,443 |
| Accumulated deficit | (54,191,053) | (33,040,842) |
| Total stockholders’ equity | 39,828,245 | 54,311,918 |
| Total liabilities and stockholders’ equity | $44,740,761 | $63,999,919 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.